| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scavenger Receptors, Class E | 94 | 2023 | 204 | 21.410 |
Why?
|
| Atherosclerosis | 64 | 2023 | 224 | 16.700 |
Why?
|
| Lipoproteins, LDL | 59 | 2023 | 169 | 12.030 |
Why?
|
| Cardiovascular Diseases | 38 | 2025 | 486 | 10.770 |
Why?
|
| Endothelium, Vascular | 47 | 2019 | 261 | 7.370 |
Why?
|
| Hypertension | 29 | 2022 | 565 | 6.780 |
Why?
|
| Angiotensin II | 33 | 2022 | 162 | 6.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 23 | 2023 | 145 | 5.150 |
Why?
|
| Myocardial Infarction | 23 | 2023 | 413 | 5.090 |
Why?
|
| Autophagy | 19 | 2021 | 197 | 5.040 |
Why?
|
| Aspirin | 15 | 2021 | 115 | 4.910 |
Why?
|
| Coronary Disease | 15 | 2021 | 152 | 4.740 |
Why?
|
| Myocytes, Cardiac | 17 | 2022 | 145 | 4.730 |
Why?
|
| Myocardium | 24 | 2023 | 480 | 4.720 |
Why?
|
| Heart Failure | 16 | 2023 | 571 | 4.580 |
Why?
|
| Oxidative Stress | 40 | 2019 | 810 | 4.430 |
Why?
|
| Humans | 294 | 2025 | 52336 | 4.430 |
Why?
|
| Apoptosis | 28 | 2024 | 1127 | 4.340 |
Why?
|
| Animals | 158 | 2025 | 13523 | 4.300 |
Why?
|
| Inflammation | 27 | 2023 | 642 | 4.270 |
Why?
|
| Coronary Artery Disease | 23 | 2019 | 297 | 4.250 |
Why?
|
| Receptors, LDL | 29 | 2023 | 73 | 4.200 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 188 | 3.750 |
Why?
|
| Endothelial Cells | 22 | 2016 | 283 | 3.740 |
Why?
|
| Fibroblasts | 15 | 2021 | 359 | 3.620 |
Why?
|
| Myocardial Ischemia | 15 | 2021 | 125 | 3.550 |
Why?
|
| Reactive Oxygen Species | 35 | 2020 | 425 | 3.280 |
Why?
|
| Pneumonia, Viral | 6 | 2020 | 177 | 3.260 |
Why?
|
| Cells, Cultured | 60 | 2020 | 1589 | 3.180 |
Why?
|
| Myocardial Reperfusion Injury | 15 | 2016 | 53 | 3.040 |
Why?
|
| Inflammasomes | 9 | 2020 | 66 | 2.960 |
Why?
|
| Pandemics | 9 | 2021 | 585 | 2.950 |
Why?
|
| Mice | 67 | 2023 | 5965 | 2.740 |
Why?
|
| Coronary Vessels | 19 | 2015 | 169 | 2.690 |
Why?
|
| Inflammation Mediators | 10 | 2021 | 117 | 2.650 |
Why?
|
| Dyslipidemias | 11 | 2020 | 42 | 2.640 |
Why?
|
| Risk Assessment | 18 | 2022 | 1323 | 2.600 |
Why?
|
| Myocytes, Smooth Muscle | 10 | 2024 | 95 | 2.580 |
Why?
|
| Receptor, Angiotensin, Type 1 | 15 | 2020 | 56 | 2.540 |
Why?
|
| Ventricular Remodeling | 9 | 2021 | 65 | 2.520 |
Why?
|
| Mice, Knockout | 34 | 2020 | 909 | 2.510 |
Why?
|
| Gene Expression Regulation | 27 | 2019 | 1006 | 2.440 |
Why?
|
| Collagen | 10 | 2016 | 212 | 2.430 |
Why?
|
| Risk Factors | 48 | 2024 | 3872 | 2.430 |
Why?
|
| Arteries | 11 | 2020 | 94 | 2.420 |
Why?
|
| Signal Transduction | 34 | 2024 | 1716 | 2.400 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 6 | 2016 | 28 | 2.390 |
Why?
|
| Atrial Fibrillation | 9 | 2024 | 200 | 2.150 |
Why?
|
| MicroRNAs | 8 | 2018 | 387 | 2.140 |
Why?
|
| Blood Pressure | 20 | 2022 | 534 | 2.100 |
Why?
|
| DNA, Mitochondrial | 5 | 2016 | 114 | 2.080 |
Why?
|
| Exosomes | 4 | 2023 | 56 | 2.020 |
Why?
|
| Endocarditis | 5 | 2016 | 31 | 2.000 |
Why?
|
| Mice, Inbred C57BL | 33 | 2023 | 1903 | 1.990 |
Why?
|
| Cardiotonic Agents | 5 | 2018 | 84 | 1.930 |
Why?
|
| Cardiovascular System | 7 | 2023 | 55 | 1.930 |
Why?
|
| Stroke | 12 | 2024 | 509 | 1.900 |
Why?
|
| Macrophages | 11 | 2018 | 378 | 1.880 |
Why?
|
| Muscle, Smooth, Vascular | 6 | 2024 | 137 | 1.870 |
Why?
|
| Heart Valve Prosthesis Implantation | 5 | 2017 | 96 | 1.860 |
Why?
|
| Heart Valve Diseases | 4 | 2015 | 53 | 1.860 |
Why?
|
| Streptococcal Infections | 4 | 2015 | 49 | 1.850 |
Why?
|
| Ventricular Function, Left | 6 | 2022 | 172 | 1.850 |
Why?
|
| Receptor, Angiotensin, Type 2 | 7 | 2013 | 23 | 1.840 |
Why?
|
| Cytokines | 16 | 2022 | 625 | 1.830 |
Why?
|
| Primary Prevention | 3 | 2019 | 45 | 1.790 |
Why?
|
| Antihypertensive Agents | 4 | 2022 | 131 | 1.760 |
Why?
|
| Antioxidants | 16 | 2017 | 258 | 1.750 |
Why?
|
| Renin-Angiotensin System | 12 | 2020 | 56 | 1.740 |
Why?
|
| Diabetes Mellitus | 11 | 2019 | 315 | 1.700 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2018 | 166 | 1.680 |
Why?
|
| Premature Birth | 3 | 2019 | 149 | 1.660 |
Why?
|
| Hypoglycemic Agents | 8 | 2015 | 210 | 1.650 |
Why?
|
| NF-kappa B | 22 | 2022 | 328 | 1.640 |
Why?
|
| Heart Diseases | 4 | 2022 | 222 | 1.640 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 3 | 2022 | 29 | 1.630 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2012 | 183 | 1.620 |
Why?
|
| Angiotensin Receptor Antagonists | 4 | 2020 | 20 | 1.610 |
Why?
|
| DNA Damage | 5 | 2016 | 307 | 1.580 |
Why?
|
| Neovascularization, Physiologic | 5 | 2014 | 86 | 1.580 |
Why?
|
| Thiazolidinediones | 9 | 2013 | 84 | 1.580 |
Why?
|
| Kidney Diseases | 6 | 2020 | 220 | 1.570 |
Why?
|
| Cell Proliferation | 14 | 2017 | 1029 | 1.570 |
Why?
|
| Staphylococcal Infections | 4 | 2015 | 280 | 1.560 |
Why?
|
| Interleukin-1beta | 6 | 2021 | 86 | 1.550 |
Why?
|
| Male | 88 | 2023 | 26696 | 1.540 |
Why?
|
| Neovascularization, Pathologic | 10 | 2016 | 158 | 1.530 |
Why?
|
| Matrix Metalloproteinase 1 | 12 | 2005 | 25 | 1.520 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 9 | 2016 | 102 | 1.500 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2022 | 19 | 1.500 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2022 | 24 | 1.490 |
Why?
|
| Toll-Like Receptor 4 | 5 | 2020 | 50 | 1.480 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2020 | 78 | 1.470 |
Why?
|
| Thromboembolism | 3 | 2021 | 50 | 1.440 |
Why?
|
| Coronary Angiography | 10 | 2015 | 366 | 1.440 |
Why?
|
| Fluorobenzenes | 5 | 2009 | 21 | 1.430 |
Why?
|
| Kidney Failure, Chronic | 3 | 2022 | 210 | 1.430 |
Why?
|
| Transforming Growth Factor beta1 | 8 | 2014 | 62 | 1.410 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2022 | 181 | 1.410 |
Why?
|
| Glucagon-Like Peptide 1 | 6 | 2016 | 33 | 1.390 |
Why?
|
| Sulfonamides | 6 | 2009 | 133 | 1.370 |
Why?
|
| Collagen Type I | 9 | 2007 | 83 | 1.340 |
Why?
|
| Plaque, Atherosclerotic | 7 | 2023 | 44 | 1.320 |
Why?
|
| Heart | 10 | 2020 | 357 | 1.320 |
Why?
|
| Pyrimidines | 5 | 2009 | 199 | 1.290 |
Why?
|
| Aged | 40 | 2022 | 10109 | 1.270 |
Why?
|
| Aging | 7 | 2016 | 708 | 1.270 |
Why?
|
| Lipopolysaccharides | 8 | 2019 | 207 | 1.260 |
Why?
|
| Thiamine | 2 | 2019 | 15 | 1.240 |
Why?
|
| Macrophages, Peritoneal | 3 | 2020 | 32 | 1.240 |
Why?
|
| Foam Cells | 4 | 2018 | 17 | 1.230 |
Why?
|
| Up-Regulation | 14 | 2015 | 462 | 1.210 |
Why?
|
| Receptors, Scavenger | 5 | 2015 | 29 | 1.190 |
Why?
|
| Dietary Supplements | 5 | 2019 | 464 | 1.180 |
Why?
|
| Carrier Proteins | 4 | 2014 | 326 | 1.180 |
Why?
|
| Female | 55 | 2024 | 28105 | 1.160 |
Why?
|
| Stress, Mechanical | 4 | 2020 | 95 | 1.120 |
Why?
|
| Myocarditis | 2 | 2021 | 49 | 1.110 |
Why?
|
| Hemodynamics | 6 | 2020 | 261 | 1.090 |
Why?
|
| Proprotein Convertases | 3 | 2016 | 8 | 1.080 |
Why?
|
| Transforming Growth Factor beta | 5 | 2007 | 139 | 1.080 |
Why?
|
| Stroke Volume | 6 | 2022 | 153 | 1.070 |
Why?
|
| Cell Enlargement | 3 | 2012 | 7 | 1.070 |
Why?
|
| Takotsubo Cardiomyopathy | 2 | 2020 | 22 | 1.060 |
Why?
|
| Cell Line | 16 | 2021 | 1045 | 1.060 |
Why?
|
| Anticoagulants | 2 | 2020 | 267 | 1.060 |
Why?
|
| Renal Dialysis | 4 | 2022 | 179 | 1.060 |
Why?
|
| Disease Models, Animal | 18 | 2021 | 1484 | 1.050 |
Why?
|
| PPAR gamma | 4 | 2013 | 73 | 1.050 |
Why?
|
| Cause of Death | 6 | 2020 | 160 | 1.050 |
Why?
|
| Transcription, Genetic | 6 | 2012 | 385 | 1.020 |
Why?
|
| Cardiomyopathies | 3 | 2022 | 123 | 1.020 |
Why?
|
| Protein Kinase C | 5 | 2014 | 70 | 1.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2022 | 561 | 1.020 |
Why?
|
| Proteomics | 2 | 2021 | 326 | 1.020 |
Why?
|
| Diabetes Complications | 7 | 2015 | 123 | 1.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 6 | 2011 | 136 | 1.010 |
Why?
|
| Receptors, Glucagon | 3 | 2014 | 9 | 0.990 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2021 | 122 | 0.980 |
Why?
|
| Endothelin-1 | 4 | 2024 | 34 | 0.980 |
Why?
|
| Aorta | 10 | 2015 | 169 | 0.980 |
Why?
|
| Fibrosis | 10 | 2021 | 197 | 0.980 |
Why?
|
| Antigens, CD | 6 | 2013 | 219 | 0.980 |
Why?
|
| Middle Aged | 36 | 2022 | 13014 | 0.970 |
Why?
|
| Curcumin | 3 | 2010 | 20 | 0.960 |
Why?
|
| Gene Expression | 14 | 2016 | 623 | 0.960 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2011 | 184 | 0.950 |
Why?
|
| Matrix Metalloproteinases | 6 | 2012 | 47 | 0.940 |
Why?
|
| Down-Regulation | 11 | 2013 | 347 | 0.930 |
Why?
|
| Cytoskeleton | 2 | 2016 | 39 | 0.930 |
Why?
|
| Serine Endopeptidases | 2 | 2015 | 50 | 0.920 |
Why?
|
| Tumor Necrosis Factor-alpha | 13 | 2022 | 397 | 0.910 |
Why?
|
| Oxygen | 4 | 2014 | 336 | 0.910 |
Why?
|
| Treatment Outcome | 26 | 2022 | 5407 | 0.890 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2020 | 27 | 0.890 |
Why?
|
| Apoptosis Regulatory Proteins | 7 | 2015 | 87 | 0.890 |
Why?
|
| RNA, Messenger | 23 | 2012 | 1142 | 0.880 |
Why?
|
| Arteriosclerosis | 8 | 2004 | 54 | 0.870 |
Why?
|
| Receptors, Oxidized LDL | 15 | 2023 | 15 | 0.870 |
Why?
|
| Circadian Rhythm | 2 | 2022 | 91 | 0.870 |
Why?
|
| Hepatitis C, Chronic | 2 | 2015 | 86 | 0.870 |
Why?
|
| Stents | 7 | 2011 | 351 | 0.850 |
Why?
|
| Sepsis | 3 | 2021 | 229 | 0.850 |
Why?
|
| Hyperlipidemias | 6 | 2011 | 52 | 0.840 |
Why?
|
| Cell Movement | 7 | 2021 | 277 | 0.830 |
Why?
|
| Mitogen-Activated Protein Kinases | 10 | 2015 | 155 | 0.830 |
Why?
|
| Blood Coagulation | 3 | 2020 | 60 | 0.800 |
Why?
|
| Kidney | 5 | 2020 | 708 | 0.800 |
Why?
|
| Carotid Artery, Common | 6 | 2013 | 44 | 0.800 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2010 | 1162 | 0.790 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2022 | 89 | 0.780 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2022 | 37 | 0.780 |
Why?
|
| Spirituality | 1 | 2022 | 31 | 0.770 |
Why?
|
| Obesity | 10 | 2021 | 1162 | 0.770 |
Why?
|
| Heart Injuries | 1 | 2022 | 16 | 0.760 |
Why?
|
| Time Factors | 18 | 2022 | 2957 | 0.760 |
Why?
|
| Lignans | 1 | 2021 | 7 | 0.760 |
Why?
|
| Intracranial Thrombosis | 1 | 2022 | 16 | 0.760 |
Why?
|
| Cell Division | 3 | 2012 | 291 | 0.750 |
Why?
|
| Brain | 6 | 2023 | 1323 | 0.750 |
Why?
|
| Cell Hypoxia | 6 | 2018 | 83 | 0.750 |
Why?
|
| Tocopherols | 3 | 2015 | 6 | 0.750 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 11 | 2016 | 95 | 0.750 |
Why?
|
| Neoplasms | 5 | 2018 | 1305 | 0.740 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2022 | 594 | 0.740 |
Why?
|
| Albuminuria | 4 | 2022 | 49 | 0.730 |
Why?
|
| Diet, High-Fat | 4 | 2020 | 237 | 0.720 |
Why?
|
| Retrospective Studies | 17 | 2023 | 6578 | 0.720 |
Why?
|
| Myocardial Contraction | 2 | 2018 | 112 | 0.710 |
Why?
|
| Capillaries | 4 | 2014 | 49 | 0.710 |
Why?
|
| Colchicine | 1 | 2021 | 24 | 0.710 |
Why?
|
| Loneliness | 1 | 2021 | 14 | 0.710 |
Why?
|
| Drug Chronotherapy | 1 | 2020 | 1 | 0.700 |
Why?
|
| Survival Rate | 7 | 2021 | 940 | 0.700 |
Why?
|
| Scavenger Receptors, Class A | 4 | 2018 | 39 | 0.690 |
Why?
|
| Survivors | 2 | 2024 | 118 | 0.690 |
Why?
|
| Echocardiography | 4 | 2017 | 412 | 0.690 |
Why?
|
| Virus Internalization | 1 | 2020 | 20 | 0.690 |
Why?
|
| Troponin I | 1 | 2020 | 19 | 0.680 |
Why?
|
| Rats | 27 | 2022 | 3202 | 0.680 |
Why?
|
| Lipid Metabolism | 4 | 2018 | 188 | 0.670 |
Why?
|
| Superoxide Dismutase | 9 | 2014 | 120 | 0.670 |
Why?
|
| Cholesterol, Dietary | 4 | 2009 | 19 | 0.660 |
Why?
|
| Brain Ischemia | 2 | 2019 | 161 | 0.660 |
Why?
|
| Prognosis | 10 | 2021 | 2094 | 0.660 |
Why?
|
| Sex Characteristics | 3 | 2016 | 198 | 0.660 |
Why?
|
| Lung Diseases | 1 | 2021 | 86 | 0.660 |
Why?
|
| Adult | 25 | 2022 | 14139 | 0.660 |
Why?
|
| Genetic Therapy | 7 | 2010 | 120 | 0.650 |
Why?
|
| Blood Glucose | 2 | 2015 | 471 | 0.650 |
Why?
|
| Proteome | 1 | 2021 | 170 | 0.650 |
Why?
|
| Cardiovascular Agents | 3 | 2009 | 60 | 0.650 |
Why?
|
| Heart Ventricles | 4 | 2020 | 268 | 0.640 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 6 | 2020 | 44 | 0.640 |
Why?
|
| Cholesterol, LDL | 3 | 2025 | 43 | 0.640 |
Why?
|
| Coronary Restenosis | 4 | 2011 | 32 | 0.640 |
Why?
|
| Antithrombins | 1 | 2019 | 19 | 0.620 |
Why?
|
| Cholesterol | 9 | 2025 | 156 | 0.620 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2014 | 186 | 0.620 |
Why?
|
| Vitamin E | 2 | 2018 | 77 | 0.620 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 407 | 0.610 |
Why?
|
| Apolipoproteins E | 2 | 2018 | 57 | 0.610 |
Why?
|
| Suicide | 1 | 2020 | 85 | 0.610 |
Why?
|
| Diabetic Nephropathies | 1 | 2019 | 61 | 0.610 |
Why?
|
| Mitochondria | 7 | 2018 | 428 | 0.610 |
Why?
|
| Phosphorylation | 10 | 2024 | 531 | 0.600 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2014 | 106 | 0.600 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2018 | 29 | 0.600 |
Why?
|
| Thiamine Deficiency | 1 | 2018 | 8 | 0.590 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 3 | 2013 | 39 | 0.590 |
Why?
|
| Transcription Factors | 5 | 2012 | 574 | 0.590 |
Why?
|
| C-Reactive Protein | 4 | 2007 | 155 | 0.590 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 289 | 0.590 |
Why?
|
| Warfarin | 1 | 2019 | 83 | 0.580 |
Why?
|
| Lipid Peroxidation | 8 | 2014 | 97 | 0.580 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2016 | 43 | 0.580 |
Why?
|
| Pravastatin | 3 | 2007 | 18 | 0.580 |
Why?
|
| Promoter Regions, Genetic | 4 | 2011 | 474 | 0.580 |
Why?
|
| Hepatitis C Antibodies | 2 | 2015 | 19 | 0.580 |
Why?
|
| Nitric Oxide Synthase Type III | 9 | 2013 | 82 | 0.580 |
Why?
|
| Blotting, Western | 11 | 2021 | 596 | 0.570 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2022 | 320 | 0.570 |
Why?
|
| Health Status Disparities | 1 | 2020 | 216 | 0.570 |
Why?
|
| Follow-Up Studies | 11 | 2017 | 2268 | 0.560 |
Why?
|
| Losartan | 6 | 2012 | 27 | 0.560 |
Why?
|
| Adaptive Immunity | 1 | 2017 | 33 | 0.560 |
Why?
|
| Medication Adherence | 1 | 2019 | 133 | 0.560 |
Why?
|
| Membrane Glycoproteins | 3 | 2015 | 244 | 0.560 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 2014 | 50 | 0.550 |
Why?
|
| Comorbidity | 7 | 2020 | 624 | 0.550 |
Why?
|
| Hepacivirus | 2 | 2015 | 106 | 0.540 |
Why?
|
| Cell Transdifferentiation | 1 | 2017 | 8 | 0.540 |
Why?
|
| Xanthine Oxidase | 1 | 2017 | 14 | 0.540 |
Why?
|
| Hospitalization | 7 | 2022 | 732 | 0.540 |
Why?
|
| United States | 15 | 2019 | 5182 | 0.530 |
Why?
|
| Thrombosis | 3 | 2022 | 253 | 0.530 |
Why?
|
| Rats, Sprague-Dawley | 20 | 2018 | 1552 | 0.530 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2012 | 39 | 0.520 |
Why?
|
| Immunity, Innate | 1 | 2017 | 117 | 0.520 |
Why?
|
| Coronary Stenosis | 4 | 2011 | 98 | 0.520 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2014 | 81 | 0.520 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 3391 | 0.520 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2010 | 188 | 0.520 |
Why?
|
| Polymorphism, Genetic | 1 | 2017 | 185 | 0.520 |
Why?
|
| Incidence | 8 | 2024 | 1059 | 0.510 |
Why?
|
| Incretins | 1 | 2016 | 7 | 0.510 |
Why?
|
| Metformin | 2 | 2015 | 76 | 0.510 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 64 | 0.510 |
Why?
|
| Clinical Trials as Topic | 8 | 2018 | 468 | 0.510 |
Why?
|
| Endocytosis | 2 | 2014 | 55 | 0.510 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 76 | 0.510 |
Why?
|
| Hypercholesterolemia | 2 | 2009 | 39 | 0.510 |
Why?
|
| Heart Valve Prosthesis | 1 | 2017 | 86 | 0.510 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 4 | 2015 | 40 | 0.500 |
Why?
|
| Calpain | 2 | 2015 | 26 | 0.500 |
Why?
|
| Oxidation-Reduction | 8 | 2012 | 328 | 0.500 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2006 | 22 | 0.500 |
Why?
|
| Transportation of Patients | 1 | 2016 | 38 | 0.500 |
Why?
|
| Age Factors | 5 | 2021 | 1127 | 0.490 |
Why?
|
| Artifacts | 1 | 2016 | 55 | 0.490 |
Why?
|
| RNA, Untranslated | 1 | 2015 | 15 | 0.490 |
Why?
|
| RNA Interference | 4 | 2018 | 186 | 0.480 |
Why?
|
| Chronic Disease | 5 | 2022 | 583 | 0.480 |
Why?
|
| Systole | 2 | 2014 | 73 | 0.480 |
Why?
|
| Autonomic Nervous System | 1 | 2016 | 60 | 0.480 |
Why?
|
| Simvastatin | 5 | 2009 | 29 | 0.480 |
Why?
|
| Tetrazoles | 3 | 2005 | 41 | 0.480 |
Why?
|
| Lipoproteins | 4 | 2010 | 40 | 0.470 |
Why?
|
| Benzimidazoles | 3 | 2005 | 50 | 0.470 |
Why?
|
| Blood Platelets | 4 | 2023 | 256 | 0.470 |
Why?
|
| Shear Strength | 1 | 2015 | 11 | 0.470 |
Why?
|
| Cell Adhesion Molecules | 4 | 2012 | 87 | 0.470 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 78 | 0.470 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 187 | 0.470 |
Why?
|
| Transfection | 7 | 2017 | 372 | 0.460 |
Why?
|
| Ligands | 5 | 2022 | 207 | 0.460 |
Why?
|
| Multiple Myeloma | 4 | 2017 | 3049 | 0.450 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 55 | 0.450 |
Why?
|
| Cadherins | 2 | 2012 | 63 | 0.450 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2014 | 33 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2012 | 172 | 0.440 |
Why?
|
| Adenoviridae | 2 | 2022 | 46 | 0.440 |
Why?
|
| Calcinosis | 3 | 2009 | 51 | 0.440 |
Why?
|
| Salicylates | 2 | 2012 | 14 | 0.440 |
Why?
|
| Body Weight | 3 | 2012 | 522 | 0.440 |
Why?
|
| Eicosapentaenoic Acid | 3 | 2009 | 24 | 0.440 |
Why?
|
| Cell-Derived Microparticles | 2 | 2012 | 20 | 0.440 |
Why?
|
| Epithelial Cells | 2 | 2012 | 215 | 0.430 |
Why?
|
| Smoking | 2 | 2015 | 518 | 0.430 |
Why?
|
| Flavoproteins | 2 | 2004 | 5 | 0.420 |
Why?
|
| Nitric Oxide | 7 | 2020 | 244 | 0.420 |
Why?
|
| Hospital Mortality | 3 | 2014 | 428 | 0.420 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2009 | 76 | 0.420 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 113 | 0.420 |
Why?
|
| Demography | 1 | 2013 | 92 | 0.420 |
Why?
|
| Nitric Oxide Synthase | 5 | 2009 | 64 | 0.420 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2024 | 29 | 0.420 |
Why?
|
| Pregnancy | 4 | 2022 | 2675 | 0.420 |
Why?
|
| rho-Associated Kinases | 2 | 2024 | 18 | 0.410 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 323 | 0.410 |
Why?
|
| Microspheres | 2 | 2010 | 20 | 0.410 |
Why?
|
| Amyloidosis | 1 | 2014 | 85 | 0.410 |
Why?
|
| Ultrasonography, Interventional | 2 | 2011 | 138 | 0.410 |
Why?
|
| RNA, Viral | 4 | 2021 | 125 | 0.410 |
Why?
|
| Amlodipine | 2 | 2009 | 14 | 0.400 |
Why?
|
| Mammary Glands, Human | 1 | 2012 | 14 | 0.400 |
Why?
|
| Dependovirus | 9 | 2010 | 103 | 0.400 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2021 | 69 | 0.400 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 19 | 0.400 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2012 | 12 | 0.400 |
Why?
|
| Prevalence | 6 | 2020 | 1007 | 0.400 |
Why?
|
| Caenorhabditis elegans | 2 | 2017 | 136 | 0.400 |
Why?
|
| alpha-Tocopherol | 3 | 2018 | 9 | 0.400 |
Why?
|
| Axons | 1 | 2012 | 48 | 0.390 |
Why?
|
| Residence Characteristics | 1 | 2013 | 160 | 0.390 |
Why?
|
| Drug Therapy, Combination | 7 | 2016 | 395 | 0.390 |
Why?
|
| Diet, Vegetarian | 2 | 2022 | 6 | 0.390 |
Why?
|
| Webcasts as Topic | 1 | 2012 | 4 | 0.390 |
Why?
|
| Catenins | 1 | 2012 | 2 | 0.390 |
Why?
|
| Adherens Junctions | 1 | 2012 | 4 | 0.390 |
Why?
|
| After-Hours Care | 1 | 2012 | 12 | 0.380 |
Why?
|
| Consumer Health Information | 1 | 2012 | 19 | 0.380 |
Why?
|
| Gene Deletion | 5 | 2013 | 276 | 0.380 |
Why?
|
| DNA Methylation | 2 | 2019 | 592 | 0.380 |
Why?
|
| Decorin | 1 | 2011 | 7 | 0.380 |
Why?
|
| Disease Progression | 6 | 2023 | 870 | 0.380 |
Why?
|
| Neurons | 2 | 2015 | 418 | 0.380 |
Why?
|
| Calcium Channel Blockers | 2 | 2009 | 60 | 0.380 |
Why?
|
| Membrane Proteins | 3 | 2014 | 340 | 0.380 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2016 | 307 | 0.370 |
Why?
|
| Cell Adhesion | 7 | 2015 | 164 | 0.370 |
Why?
|
| Poverty | 1 | 2013 | 219 | 0.370 |
Why?
|
| Patient Admission | 1 | 2012 | 78 | 0.370 |
Why?
|
| Seasons | 1 | 2012 | 91 | 0.370 |
Why?
|
| Cell Culture Techniques | 5 | 2015 | 99 | 0.370 |
Why?
|
| Hyperphagia | 1 | 2011 | 9 | 0.360 |
Why?
|
| Arkansas | 5 | 2016 | 2028 | 0.360 |
Why?
|
| Sex Factors | 3 | 2020 | 727 | 0.360 |
Why?
|
| Cell Differentiation | 1 | 2014 | 674 | 0.360 |
Why?
|
| Predictive Value of Tests | 6 | 2017 | 943 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2012 | 1377 | 0.360 |
Why?
|
| Platelet Activation | 2 | 2011 | 47 | 0.360 |
Why?
|
| Vasoconstrictor Agents | 2 | 2010 | 81 | 0.360 |
Why?
|
| Drug-Eluting Stents | 3 | 2008 | 94 | 0.360 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2010 | 583 | 0.360 |
Why?
|
| Vitamins | 2 | 2019 | 64 | 0.360 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 88 | 0.360 |
Why?
|
| Antimitotic Agents | 1 | 2010 | 4 | 0.350 |
Why?
|
| Estrogens | 2 | 2015 | 223 | 0.350 |
Why?
|
| Registries | 3 | 2019 | 580 | 0.350 |
Why?
|
| Drug Prescriptions | 2 | 2019 | 102 | 0.350 |
Why?
|
| Oxidants | 2 | 2007 | 51 | 0.350 |
Why?
|
| Heat-Shock Proteins | 5 | 2023 | 105 | 0.350 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2018 | 65 | 0.350 |
Why?
|
| Acute Coronary Syndrome | 2 | 2013 | 80 | 0.350 |
Why?
|
| Saphenous Vein | 2 | 2008 | 63 | 0.340 |
Why?
|
| Cytoprotection | 3 | 2019 | 33 | 0.340 |
Why?
|
| Cannabinoids | 1 | 2012 | 105 | 0.340 |
Why?
|
| Vena Cava, Superior | 1 | 2010 | 22 | 0.330 |
Why?
|
| Cell Survival | 4 | 2019 | 602 | 0.330 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 801 | 0.330 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1222 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 2 | 2011 | 487 | 0.330 |
Why?
|
| Nuclear Medicine | 1 | 2010 | 24 | 0.330 |
Why?
|
| Growth Inhibitors | 1 | 2010 | 26 | 0.330 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 66 | 0.330 |
Why?
|
| Leukocytes | 3 | 2017 | 61 | 0.330 |
Why?
|
| Heart Rate | 5 | 2018 | 319 | 0.330 |
Why?
|
| Mitochondrial Proteins | 4 | 2015 | 90 | 0.320 |
Why?
|
| Emergency Service, Hospital | 2 | 2011 | 521 | 0.320 |
Why?
|
| Angiotensin III | 1 | 2009 | 2 | 0.320 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2020 | 12 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2012 | 129 | 0.320 |
Why?
|
| Tunica Intima | 4 | 2008 | 55 | 0.320 |
Why?
|
| Platelet Aggregation | 3 | 2011 | 70 | 0.320 |
Why?
|
| Serine | 2 | 2022 | 36 | 0.320 |
Why?
|
| Carotid Artery Diseases | 2 | 2008 | 31 | 0.320 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2012 | 412 | 0.320 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2011 | 127 | 0.310 |
Why?
|
| Cholesterol, HDL | 3 | 2022 | 38 | 0.310 |
Why?
|
| Cardiomegaly | 1 | 2009 | 57 | 0.310 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 293 | 0.310 |
Why?
|
| Cannabis | 1 | 2012 | 150 | 0.310 |
Why?
|
| Venous Thrombosis | 1 | 2010 | 90 | 0.310 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2008 | 181 | 0.310 |
Why?
|
| Genetic Vectors | 4 | 2007 | 128 | 0.300 |
Why?
|
| Depression | 3 | 2020 | 600 | 0.300 |
Why?
|
| Survival Analysis | 3 | 2020 | 671 | 0.300 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 3 | 2004 | 12 | 0.300 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2022 | 57 | 0.300 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2005 | 67 | 0.300 |
Why?
|
| Immunoglobulins | 1 | 2009 | 76 | 0.300 |
Why?
|
| Proteoglycans | 2 | 2022 | 87 | 0.290 |
Why?
|
| Genomics | 1 | 2010 | 270 | 0.290 |
Why?
|
| Nitric Oxide Synthase Type II | 4 | 2012 | 63 | 0.290 |
Why?
|
| Erythropoietin | 1 | 2008 | 50 | 0.290 |
Why?
|
| Heme Oxygenase-1 | 1 | 2007 | 18 | 0.290 |
Why?
|
| Diet | 2 | 2022 | 588 | 0.290 |
Why?
|
| Anti-Infective Agents | 2 | 2020 | 106 | 0.280 |
Why?
|
| Enzyme Activation | 5 | 2015 | 272 | 0.280 |
Why?
|
| Progestins | 1 | 2007 | 11 | 0.280 |
Why?
|
| Age Distribution | 4 | 2011 | 174 | 0.280 |
Why?
|
| Hormone Replacement Therapy | 1 | 2007 | 21 | 0.280 |
Why?
|
| Fish Oils | 2 | 2009 | 14 | 0.280 |
Why?
|
| Adenosine Diphosphate | 1 | 2007 | 19 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 1543 | 0.270 |
Why?
|
| MAP Kinase Signaling System | 5 | 2020 | 127 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2006 | 506 | 0.270 |
Why?
|
| Bradycardia | 2 | 2004 | 37 | 0.270 |
Why?
|
| Heart Arrest | 2 | 2018 | 137 | 0.270 |
Why?
|
| Coronary Artery Bypass | 4 | 2010 | 125 | 0.270 |
Why?
|
| Immunity | 2 | 2022 | 39 | 0.270 |
Why?
|
| Acute Disease | 5 | 2022 | 374 | 0.270 |
Why?
|
| Catheterization | 3 | 2005 | 95 | 0.260 |
Why?
|
| Transcriptional Activation | 2 | 2024 | 128 | 0.260 |
Why?
|
| Cardiac Output, Low | 1 | 2006 | 12 | 0.260 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenases | 1 | 2006 | 1 | 0.260 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2007 | 59 | 0.260 |
Why?
|
| Cell Line, Transformed | 2 | 2021 | 75 | 0.260 |
Why?
|
| RNA, Small Interfering | 3 | 2018 | 218 | 0.260 |
Why?
|
| Endothelium | 2 | 2003 | 38 | 0.260 |
Why?
|
| Baroreflex | 2 | 2018 | 3 | 0.250 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2004 | 7 | 0.250 |
Why?
|
| Polyurethanes | 1 | 2006 | 10 | 0.250 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2006 | 3 | 0.250 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2010 | 224 | 0.250 |
Why?
|
| Hypolipidemic Agents | 2 | 2020 | 30 | 0.250 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2006 | 14 | 0.250 |
Why?
|
| Monocytes | 3 | 2014 | 130 | 0.250 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 33 | 0.250 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2021 | 97 | 0.250 |
Why?
|
| Calcineurin | 1 | 2007 | 76 | 0.250 |
Why?
|
| Immunosuppressive Agents | 2 | 2006 | 243 | 0.250 |
Why?
|
| Malondialdehyde | 4 | 2013 | 54 | 0.250 |
Why?
|
| Reperfusion Injury | 2 | 2003 | 72 | 0.250 |
Why?
|
| Defibrillators, Implantable | 1 | 2007 | 68 | 0.250 |
Why?
|
| Outpatients | 1 | 2006 | 125 | 0.250 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2006 | 64 | 0.250 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2006 | 60 | 0.250 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2005 | 35 | 0.240 |
Why?
|
| Neurodegenerative Diseases | 2 | 2017 | 81 | 0.240 |
Why?
|
| Superoxides | 5 | 2012 | 46 | 0.240 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2005 | 62 | 0.240 |
Why?
|
| Prosthesis Design | 3 | 2017 | 255 | 0.240 |
Why?
|
| Severity of Illness Index | 5 | 2007 | 1021 | 0.240 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2012 | 83 | 0.240 |
Why?
|
| Regional Blood Flow | 3 | 2020 | 109 | 0.230 |
Why?
|
| Hospitals | 2 | 2023 | 181 | 0.230 |
Why?
|
| Heparin | 2 | 2022 | 88 | 0.230 |
Why?
|
| Enzyme Induction | 2 | 2003 | 77 | 0.230 |
Why?
|
| Docosahexaenoic Acids | 2 | 2009 | 31 | 0.230 |
Why?
|
| Endodeoxyribonucleases | 2 | 2016 | 44 | 0.230 |
Why?
|
| Myosin-Light-Chain Phosphatase | 1 | 2024 | 3 | 0.230 |
Why?
|
| Receptors, Notch | 2 | 2015 | 28 | 0.230 |
Why?
|
| Aldehyde Dehydrogenase | 2 | 2015 | 25 | 0.220 |
Why?
|
| Viruses | 1 | 2004 | 24 | 0.220 |
Why?
|
| Cytochrome b Group | 2 | 2018 | 5 | 0.220 |
Why?
|
| Actins | 2 | 2016 | 117 | 0.220 |
Why?
|
| Caspase 3 | 4 | 2012 | 94 | 0.220 |
Why?
|
| Acetophenones | 2 | 2015 | 12 | 0.220 |
Why?
|
| Carotid Arteries | 2 | 2011 | 76 | 0.220 |
Why?
|
| Veterans | 2 | 2009 | 581 | 0.220 |
Why?
|
| Osteopontin | 3 | 2008 | 16 | 0.220 |
Why?
|
| Fibronectins | 3 | 2008 | 37 | 0.210 |
Why?
|
| Models, Statistical | 2 | 2016 | 230 | 0.210 |
Why?
|
| Septal Occluder Device | 1 | 2024 | 36 | 0.210 |
Why?
|
| Italy | 2 | 2021 | 26 | 0.210 |
Why?
|
| Foramen Ovale, Patent | 1 | 2024 | 31 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 858 | 0.210 |
Why?
|
| Ephedra | 1 | 2003 | 8 | 0.210 |
Why?
|
| Triazoles | 2 | 2014 | 115 | 0.210 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2003 | 23 | 0.210 |
Why?
|
| Interleukin-10 | 4 | 2010 | 84 | 0.210 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2023 | 50 | 0.210 |
Why?
|
| Aldehydes | 2 | 2014 | 81 | 0.210 |
Why?
|
| CD40 Ligand | 1 | 2003 | 15 | 0.210 |
Why?
|
| Pyrazines | 2 | 2014 | 190 | 0.210 |
Why?
|
| Phytotherapy | 1 | 2003 | 45 | 0.210 |
Why?
|
| Plant Preparations | 1 | 2003 | 41 | 0.200 |
Why?
|
| Genes, cdc | 1 | 2003 | 6 | 0.200 |
Why?
|
| Mechanotransduction, Cellular | 2 | 2020 | 42 | 0.200 |
Why?
|
| Bromocriptine | 1 | 2022 | 5 | 0.200 |
Why?
|
| Young Adult | 6 | 2019 | 4319 | 0.200 |
Why?
|
| Hemostasis | 1 | 2003 | 60 | 0.200 |
Why?
|
| Peripartum Period | 1 | 2022 | 15 | 0.200 |
Why?
|
| Prolactin | 1 | 2022 | 43 | 0.200 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2022 | 34 | 0.200 |
Why?
|
| STAT3 Transcription Factor | 2 | 2015 | 88 | 0.200 |
Why?
|
| Biological Transport | 2 | 2018 | 158 | 0.200 |
Why?
|
| Lung Injury | 1 | 2022 | 25 | 0.200 |
Why?
|
| Antibodies | 4 | 2010 | 152 | 0.200 |
Why?
|
| Molsidomine | 1 | 2002 | 5 | 0.200 |
Why?
|
| Nitric Oxide Donors | 1 | 2002 | 9 | 0.200 |
Why?
|
| Microscopy, Fluorescence | 3 | 2012 | 149 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 2 | 2014 | 460 | 0.190 |
Why?
|
| Cross-Sectional Studies | 4 | 2016 | 1676 | 0.190 |
Why?
|
| Infant, Newborn | 2 | 2019 | 2826 | 0.190 |
Why?
|
| Mice, Transgenic | 3 | 2015 | 563 | 0.190 |
Why?
|
| Drug Utilization | 2 | 2019 | 77 | 0.190 |
Why?
|
| Thalidomide | 1 | 2004 | 377 | 0.190 |
Why?
|
| Heptanoic Acids | 4 | 2009 | 34 | 0.190 |
Why?
|
| Cell Line, Tumor | 4 | 2017 | 1436 | 0.190 |
Why?
|
| Exercise | 2 | 2005 | 548 | 0.190 |
Why?
|
| Annexin A5 | 2 | 2012 | 14 | 0.190 |
Why?
|
| Time | 2 | 2012 | 28 | 0.190 |
Why?
|
| Carbocyanines | 2 | 2015 | 8 | 0.190 |
Why?
|
| Biological Availability | 1 | 2021 | 108 | 0.180 |
Why?
|
| Metal Nanoparticles | 1 | 2022 | 66 | 0.180 |
Why?
|
| Troponin | 1 | 2021 | 14 | 0.180 |
Why?
|
| Gold | 1 | 2022 | 85 | 0.180 |
Why?
|
| Cardiac Catheterization | 1 | 2024 | 230 | 0.180 |
Why?
|
| Protein Subunits | 3 | 2010 | 80 | 0.180 |
Why?
|
| Pneumonia | 1 | 2022 | 125 | 0.180 |
Why?
|
| Antibodies, Neutralizing | 2 | 2012 | 79 | 0.180 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2010 | 110 | 0.180 |
Why?
|
| Pyrroles | 4 | 2009 | 71 | 0.180 |
Why?
|
| Triglycerides | 1 | 2022 | 165 | 0.180 |
Why?
|
| Gout Suppressants | 1 | 2021 | 3 | 0.180 |
Why?
|
| Administration, Oral | 2 | 2019 | 451 | 0.180 |
Why?
|
| Chronotherapy | 1 | 2020 | 2 | 0.180 |
Why?
|
| Glycosides | 1 | 2020 | 19 | 0.180 |
Why?
|
| Sodium-Glucose Transporter 1 | 1 | 2020 | 6 | 0.180 |
Why?
|
| Drug Synergism | 3 | 2006 | 148 | 0.180 |
Why?
|
| Molecular Imaging | 2 | 2011 | 28 | 0.180 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2007 | 66 | 0.180 |
Why?
|
| Social Isolation | 1 | 2021 | 28 | 0.170 |
Why?
|
| Aortitis | 1 | 2020 | 4 | 0.170 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 21 | 0.170 |
Why?
|
| Transcription Factor AP-1 | 3 | 2006 | 62 | 0.170 |
Why?
|
| Ultrasonography | 4 | 2008 | 424 | 0.170 |
Why?
|
| Reference Values | 2 | 2016 | 313 | 0.170 |
Why?
|
| Models, Biological | 3 | 2016 | 743 | 0.170 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2020 | 34 | 0.170 |
Why?
|
| Enzyme Inhibitors | 3 | 2012 | 374 | 0.170 |
Why?
|
| Epinephrine | 1 | 2001 | 93 | 0.170 |
Why?
|
| Sensitivity and Specificity | 4 | 2013 | 879 | 0.170 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 66 | 0.170 |
Why?
|
| China | 1 | 2020 | 134 | 0.170 |
Why?
|
| Biological Assay | 2 | 2021 | 47 | 0.170 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 62 | 0.170 |
Why?
|
| Pregnant Women | 1 | 2021 | 70 | 0.170 |
Why?
|
| Dendritic Cells | 3 | 2007 | 136 | 0.170 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 123 | 0.170 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2019 | 13 | 0.160 |
Why?
|
| Spheroids, Cellular | 1 | 2019 | 26 | 0.160 |
Why?
|
| Cell Size | 2 | 2010 | 48 | 0.160 |
Why?
|
| Logistic Models | 4 | 2012 | 920 | 0.160 |
Why?
|
| Analysis of Variance | 3 | 2011 | 555 | 0.160 |
Why?
|
| Aorta, Thoracic | 1 | 2020 | 98 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2015 | 151 | 0.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2012 | 138 | 0.160 |
Why?
|
| Gene-Environment Interaction | 1 | 2019 | 40 | 0.160 |
Why?
|
| Cyclooxygenase 2 | 2 | 2012 | 50 | 0.160 |
Why?
|
| Extracellular Matrix | 2 | 2011 | 112 | 0.160 |
Why?
|
| Caspases | 3 | 2004 | 105 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2013 | 97 | 0.160 |
Why?
|
| Drug Combinations | 2 | 2014 | 134 | 0.160 |
Why?
|
| Sex Distribution | 2 | 2011 | 137 | 0.160 |
Why?
|
| Early Diagnosis | 2 | 2017 | 87 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 144 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 1214 | 0.150 |
Why?
|
| gamma-Tocopherol | 1 | 2018 | 2 | 0.150 |
Why?
|
| DNA, Complementary | 2 | 2012 | 137 | 0.150 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 158 | 0.150 |
Why?
|
| Antiviral Agents | 1 | 2020 | 177 | 0.150 |
Why?
|
| Protein Binding | 3 | 2016 | 680 | 0.150 |
Why?
|
| Tocotrienols | 1 | 2018 | 37 | 0.150 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 62 | 0.150 |
Why?
|
| Animals, Genetically Modified | 1 | 2018 | 52 | 0.150 |
Why?
|
| Receptors, Immunologic | 1 | 2018 | 37 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 1206 | 0.150 |
Why?
|
| Phenotype | 2 | 2011 | 799 | 0.140 |
Why?
|
| Mortality | 2 | 2013 | 104 | 0.140 |
Why?
|
| Chromans | 2 | 2013 | 35 | 0.140 |
Why?
|
| Rupture, Spontaneous | 1 | 2017 | 20 | 0.140 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2014 | 47 | 0.140 |
Why?
|
| Molecular Mimicry | 1 | 2017 | 36 | 0.140 |
Why?
|
| Fluorescent Dyes | 2 | 2015 | 91 | 0.140 |
Why?
|
| Lipids | 2 | 2009 | 157 | 0.140 |
Why?
|
| Sirtuin 1 | 2 | 2014 | 29 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 124 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2019 | 209 | 0.140 |
Why?
|
| Anti-Allergic Agents | 1 | 2017 | 16 | 0.140 |
Why?
|
| Databases, Factual | 2 | 2012 | 706 | 0.140 |
Why?
|
| Glucose | 2 | 2016 | 357 | 0.140 |
Why?
|
| Case-Control Studies | 2 | 2023 | 1201 | 0.130 |
Why?
|
| Uric Acid | 1 | 2017 | 25 | 0.130 |
Why?
|
| Adolescent | 5 | 2020 | 6692 | 0.130 |
Why?
|
| Mitral Valve | 1 | 2017 | 52 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2017 | 117 | 0.130 |
Why?
|
| Elasticity | 2 | 2007 | 19 | 0.130 |
Why?
|
| Biphenyl Compounds | 3 | 2005 | 31 | 0.130 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2017 | 52 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 134 | 0.130 |
Why?
|
| Base Sequence | 2 | 2011 | 648 | 0.130 |
Why?
|
| Pyridines | 3 | 2024 | 133 | 0.130 |
Why?
|
| Transduction, Genetic | 3 | 2007 | 44 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 82 | 0.120 |
Why?
|
| Physical Conditioning, Animal | 3 | 2005 | 62 | 0.120 |
Why?
|
| Tissue Distribution | 1 | 2016 | 174 | 0.120 |
Why?
|
| Length of Stay | 3 | 2017 | 659 | 0.120 |
Why?
|
| Myofibroblasts | 1 | 2016 | 50 | 0.120 |
Why?
|
| Atenolol | 2 | 2009 | 13 | 0.120 |
Why?
|
| Insulin Resistance | 2 | 2009 | 277 | 0.120 |
Why?
|
| Proteins | 2 | 2017 | 354 | 0.120 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2015 | 9 | 0.120 |
Why?
|
| Liver | 1 | 2021 | 1159 | 0.120 |
Why?
|
| Coronary Circulation | 3 | 2009 | 57 | 0.120 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 1110 | 0.120 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2006 | 74 | 0.120 |
Why?
|
| Hormones | 1 | 2015 | 59 | 0.120 |
Why?
|
| Vaccination | 1 | 2017 | 297 | 0.120 |
Why?
|
| SOXF Transcription Factors | 1 | 2015 | 4 | 0.120 |
Why?
|
| Recurrence | 1 | 2017 | 672 | 0.120 |
Why?
|
| Androgens | 1 | 2015 | 70 | 0.120 |
Why?
|
| Onium Compounds | 1 | 2015 | 13 | 0.120 |
Why?
|
| Receptors, CXCR4 | 1 | 2015 | 29 | 0.120 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2015 | 16 | 0.120 |
Why?
|
| Drug Design | 1 | 2015 | 121 | 0.120 |
Why?
|
| beta-Galactosidase | 1 | 2015 | 34 | 0.120 |
Why?
|
| Central Nervous System Depressants | 1 | 2015 | 80 | 0.120 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2014 | 6 | 0.120 |
Why?
|
| Binding Sites | 2 | 2006 | 379 | 0.120 |
Why?
|
| Electrocardiography | 2 | 2007 | 267 | 0.120 |
Why?
|
| Myocardial Reperfusion | 2 | 2004 | 10 | 0.110 |
Why?
|
| Thioglycolates | 1 | 2014 | 3 | 0.110 |
Why?
|
| Laminin | 1 | 2014 | 20 | 0.110 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 132 | 0.110 |
Why?
|
| Seroepidemiologic Studies | 1 | 2014 | 44 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 110 | 0.110 |
Why?
|
| Metalloendopeptidases | 1 | 2015 | 70 | 0.110 |
Why?
|
| Cytochromes c | 2 | 2012 | 28 | 0.110 |
Why?
|
| Caspase 1 | 1 | 2014 | 23 | 0.110 |
Why?
|
| Morbidity | 2 | 2008 | 141 | 0.110 |
Why?
|
| Interleukin-18 | 1 | 2014 | 27 | 0.110 |
Why?
|
| Nitriles | 1 | 2014 | 53 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 2014 | 69 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 85 | 0.110 |
Why?
|
| Catecholamines | 1 | 2014 | 44 | 0.110 |
Why?
|
| Plasmids | 2 | 2005 | 167 | 0.110 |
Why?
|
| Thrombomodulin | 2 | 2005 | 26 | 0.110 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2013 | 10 | 0.110 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2004 | 29 | 0.110 |
Why?
|
| Pyrrolidines | 1 | 2014 | 69 | 0.110 |
Why?
|
| Indomethacin | 2 | 2004 | 35 | 0.110 |
Why?
|
| Calcium | 1 | 2015 | 375 | 0.110 |
Why?
|
| Apoptosis Inducing Factor | 2 | 2004 | 4 | 0.110 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2013 | 10 | 0.110 |
Why?
|
| Protein Isoforms | 2 | 2011 | 126 | 0.110 |
Why?
|
| Fluorescence | 1 | 2013 | 30 | 0.110 |
Why?
|
| Models, Animal | 1 | 2014 | 228 | 0.100 |
Why?
|
| Alternative Splicing | 2 | 2011 | 62 | 0.100 |
Why?
|
| DNA Primers | 2 | 2011 | 209 | 0.100 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2013 | 10 | 0.100 |
Why?
|
| Viral Proteins | 2 | 2005 | 164 | 0.100 |
Why?
|
| India | 2 | 2015 | 62 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 122 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2014 | 175 | 0.100 |
Why?
|
| Homocysteine | 2 | 2004 | 126 | 0.100 |
Why?
|
| Caloric Restriction | 1 | 2013 | 38 | 0.100 |
Why?
|
| Polysaccharide-Lyases | 1 | 2012 | 7 | 0.100 |
Why?
|
| Salicylic Acid | 1 | 2012 | 5 | 0.100 |
Why?
|
| Ethanol | 1 | 2015 | 342 | 0.100 |
Why?
|
| Transcription Factor RelA | 1 | 2012 | 32 | 0.100 |
Why?
|
| Imines | 1 | 2012 | 16 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 205 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2012 | 34 | 0.100 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2012 | 58 | 0.100 |
Why?
|
| Computer Simulation | 3 | 2020 | 290 | 0.100 |
Why?
|
| bcl-X Protein | 1 | 2012 | 54 | 0.100 |
Why?
|
| Locomotion | 1 | 2012 | 85 | 0.100 |
Why?
|
| Umbilical Veins | 2 | 2009 | 22 | 0.090 |
Why?
|
| Electric Countershock | 1 | 2012 | 30 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2011 | 404 | 0.090 |
Why?
|
| Transplantation, Autologous | 1 | 2014 | 488 | 0.090 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 429 | 0.090 |
Why?
|
| Hospital Bed Capacity | 1 | 2011 | 12 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 150 | 0.090 |
Why?
|
| Embryonic Development | 1 | 2011 | 18 | 0.090 |
Why?
|
| Photoacoustic Techniques | 1 | 2011 | 24 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2012 | 203 | 0.090 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 28 | 0.090 |
Why?
|
| Medically Uninsured | 1 | 2011 | 46 | 0.090 |
Why?
|
| Hospitals, Teaching | 1 | 2011 | 53 | 0.090 |
Why?
|
| Lipogenesis | 1 | 2011 | 31 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 96 | 0.090 |
Why?
|
| Sinoatrial Node | 1 | 2011 | 3 | 0.090 |
Why?
|
| Intercellular Junctions | 1 | 2010 | 7 | 0.090 |
Why?
|
| Health Care Surveys | 1 | 2011 | 177 | 0.090 |
Why?
|
| Health Surveys | 1 | 2012 | 238 | 0.090 |
Why?
|
| Cell Migration Assays | 1 | 2010 | 2 | 0.090 |
Why?
|
| Long-Term Care | 1 | 2011 | 51 | 0.090 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 62 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 68 | 0.090 |
Why?
|
| Angiotensin II Type 2 Receptor Blockers | 2 | 2007 | 7 | 0.090 |
Why?
|
| Rabbits | 2 | 2020 | 374 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2012 | 273 | 0.080 |
Why?
|
| Life Style | 1 | 2011 | 145 | 0.080 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2010 | 25 | 0.080 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2007 | 10 | 0.080 |
Why?
|
| Interleukin-6 | 2 | 2013 | 278 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 2 | 2014 | 57 | 0.080 |
Why?
|
| Sodium Chloride | 1 | 2010 | 56 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2007 | 50 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2013 | 347 | 0.080 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2010 | 30 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 590 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 52 | 0.080 |
Why?
|
| Transcriptome | 1 | 2012 | 367 | 0.080 |
Why?
|
| NADP | 1 | 2009 | 22 | 0.080 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2009 | 17 | 0.080 |
Why?
|
| Internet | 1 | 2012 | 262 | 0.080 |
Why?
|
| Hospitals, Veterans | 1 | 2010 | 110 | 0.080 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2009 | 8 | 0.080 |
Why?
|
| Wound Healing | 1 | 2011 | 219 | 0.080 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2009 | 5 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2009 | 401 | 0.080 |
Why?
|
| Subcutaneous Fat | 1 | 2009 | 19 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 491 | 0.080 |
Why?
|
| Imidazoles | 2 | 2007 | 124 | 0.080 |
Why?
|
| Food Deprivation | 1 | 2009 | 30 | 0.080 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2009 | 4 | 0.080 |
Why?
|
| Isoproterenol | 1 | 2009 | 55 | 0.080 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2009 | 42 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2009 | 117 | 0.080 |
Why?
|
| Fasting | 1 | 2009 | 75 | 0.080 |
Why?
|
| Carotid Artery Injuries | 2 | 2005 | 12 | 0.080 |
Why?
|
| User-Computer Interface | 1 | 2009 | 79 | 0.080 |
Why?
|
| Dosage Forms | 1 | 2008 | 8 | 0.070 |
Why?
|
| Adipocytes | 1 | 2009 | 130 | 0.070 |
Why?
|
| Tissue Engineering | 2 | 2006 | 74 | 0.070 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2008 | 35 | 0.070 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 50 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 78 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2005 | 51 | 0.070 |
Why?
|
| Fatty Acids | 1 | 2009 | 151 | 0.070 |
Why?
|
| Angiotensins | 1 | 2007 | 12 | 0.070 |
Why?
|
| Drug Carriers | 1 | 2008 | 68 | 0.070 |
Why?
|
| Norepinephrine | 1 | 2008 | 112 | 0.070 |
Why?
|
| Papillomaviridae | 2 | 2005 | 105 | 0.070 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2007 | 7 | 0.070 |
Why?
|
| Feedback, Physiological | 1 | 2007 | 12 | 0.070 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2004 | 29 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 25 | 0.070 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 44 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 34 | 0.070 |
Why?
|
| Creatinine | 1 | 2008 | 149 | 0.070 |
Why?
|
| Metalloproteases | 1 | 2007 | 10 | 0.070 |
Why?
|
| Integrin alpha2beta1 | 1 | 2007 | 4 | 0.070 |
Why?
|
| Tyrosine | 1 | 2007 | 88 | 0.070 |
Why?
|
| Keratinocytes | 2 | 2005 | 93 | 0.070 |
Why?
|
| Mass Screening | 1 | 2010 | 357 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 606 | 0.070 |
Why?
|
| Myocardial Revascularization | 1 | 2007 | 21 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 49 | 0.070 |
Why?
|
| Crosses, Genetic | 1 | 2007 | 34 | 0.070 |
Why?
|
| Fibrinogen | 1 | 2007 | 34 | 0.070 |
Why?
|
| Necrosis | 2 | 2009 | 173 | 0.070 |
Why?
|
| Hysterectomy | 1 | 2007 | 90 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2009 | 239 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 192 | 0.070 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2007 | 33 | 0.070 |
Why?
|
| Women's Health | 1 | 2007 | 82 | 0.070 |
Why?
|
| Defibrillators | 1 | 2007 | 7 | 0.070 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2007 | 6 | 0.070 |
Why?
|
| Postmenopause | 1 | 2007 | 82 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 44 | 0.070 |
Why?
|
| Nanotechnology | 1 | 2007 | 29 | 0.070 |
Why?
|
| Tunica Media | 2 | 2008 | 11 | 0.070 |
Why?
|
| Vascular Resistance | 1 | 2007 | 50 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2011 | 792 | 0.070 |
Why?
|
| Emergencies | 1 | 2007 | 81 | 0.070 |
Why?
|
| Thromboxane A2 | 1 | 2006 | 12 | 0.070 |
Why?
|
| Drug Labeling | 1 | 2006 | 11 | 0.070 |
Why?
|
| Epoprostenol | 1 | 2006 | 15 | 0.070 |
Why?
|
| Diclofenac | 1 | 2006 | 10 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2006 | 19 | 0.070 |
Why?
|
| Diabetic Retinopathy | 1 | 2007 | 44 | 0.070 |
Why?
|
| Epidemiologic Studies | 1 | 2006 | 22 | 0.070 |
Why?
|
| Sulfones | 1 | 2006 | 24 | 0.070 |
Why?
|
| Lactones | 1 | 2006 | 25 | 0.070 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2007 | 41 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 1 | 2006 | 40 | 0.070 |
Why?
|
| Databases as Topic | 1 | 2006 | 39 | 0.070 |
Why?
|
| Organ Size | 1 | 2007 | 231 | 0.060 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2003 | 22 | 0.060 |
Why?
|
| Vasodilation | 1 | 2007 | 99 | 0.060 |
Why?
|
| Forecasting | 1 | 2007 | 154 | 0.060 |
Why?
|
| Renal Insufficiency | 1 | 2007 | 113 | 0.060 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2007 | 36 | 0.060 |
Why?
|
| ROC Curve | 1 | 2007 | 251 | 0.060 |
Why?
|
| Corrosion | 1 | 2006 | 4 | 0.060 |
Why?
|
| Contrast Media | 1 | 2007 | 174 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2006 | 48 | 0.060 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2006 | 5 | 0.060 |
Why?
|
| Paclitaxel | 1 | 2006 | 90 | 0.060 |
Why?
|
| Syndrome | 1 | 2006 | 247 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 71 | 0.060 |
Why?
|
| Surface Properties | 1 | 2006 | 62 | 0.060 |
Why?
|
| Hydroxycholesterols | 1 | 2005 | 9 | 0.060 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2005 | 14 | 0.060 |
Why?
|
| Materials Testing | 1 | 2006 | 55 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2006 | 119 | 0.060 |
Why?
|
| Sirolimus | 1 | 2006 | 67 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2005 | 30 | 0.060 |
Why?
|
| Genes, Viral | 1 | 2005 | 39 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2005 | 50 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2005 | 55 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2006 | 114 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 1 | 2005 | 36 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 3 | 2005 | 481 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 230 | 0.060 |
Why?
|
| Sodium Salicylate | 1 | 2005 | 4 | 0.060 |
Why?
|
| Antigens, Surface | 1 | 2005 | 47 | 0.060 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2005 | 13 | 0.060 |
Why?
|
| Urotensins | 1 | 2004 | 2 | 0.060 |
Why?
|
| Diet, Fat-Restricted | 1 | 2004 | 13 | 0.060 |
Why?
|
| Anions | 1 | 2004 | 6 | 0.060 |
Why?
|
| Skin, Artificial | 1 | 2004 | 11 | 0.060 |
Why?
|
| Diet, Mediterranean | 1 | 2004 | 10 | 0.060 |
Why?
|
| Core Binding Factors | 1 | 2004 | 3 | 0.060 |
Why?
|
| Genetic Engineering | 1 | 2004 | 23 | 0.060 |
Why?
|
| Research Design | 1 | 2007 | 354 | 0.060 |
Why?
|
| Lipoprotein(a) | 1 | 2004 | 6 | 0.060 |
Why?
|
| Marine Toxins | 1 | 2024 | 2 | 0.060 |
Why?
|
| Smad2 Protein | 1 | 2024 | 6 | 0.060 |
Why?
|
| PC12 Cells | 2 | 2015 | 25 | 0.060 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2004 | 46 | 0.060 |
Why?
|
| Milk Proteins | 1 | 2005 | 77 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2009 | 2428 | 0.060 |
Why?
|
| Oxazoles | 1 | 2024 | 9 | 0.060 |
Why?
|
| Coculture Techniques | 3 | 2012 | 145 | 0.060 |
Why?
|
| Valine | 1 | 2004 | 57 | 0.060 |
Why?
|
| Homeostasis | 1 | 2005 | 206 | 0.060 |
Why?
|
| Protective Agents | 1 | 2004 | 17 | 0.060 |
Why?
|
| Rats, Inbred SHR | 2 | 2015 | 42 | 0.060 |
Why?
|
| Virus Replication | 1 | 2005 | 150 | 0.060 |
Why?
|
| Angiotensin I | 1 | 2004 | 14 | 0.060 |
Why?
|
| Dietary Carbohydrates | 1 | 2004 | 90 | 0.060 |
Why?
|
| Amides | 1 | 2024 | 37 | 0.060 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2004 | 48 | 0.060 |
Why?
|
| Oligoribonucleotides, Antisense | 1 | 2004 | 2 | 0.050 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2003 | 2 | 0.050 |
Why?
|
| Organometallic Compounds | 1 | 2004 | 43 | 0.050 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2015 | 40 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2004 | 97 | 0.050 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2004 | 67 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2024 | 32 | 0.050 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2023 | 16 | 0.050 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2003 | 2 | 0.050 |
Why?
|
| Chlamydophila Infections | 1 | 2003 | 2 | 0.050 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 55 | 0.050 |
Why?
|
| DNA Adducts | 1 | 2004 | 79 | 0.050 |
Why?
|
| Ephedrine | 1 | 2003 | 21 | 0.050 |
Why?
|
| Platelet Count | 1 | 2023 | 75 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2004 | 97 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2003 | 76 | 0.050 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2003 | 49 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2004 | 109 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 71 | 0.050 |
Why?
|
| DNA | 2 | 2005 | 550 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2003 | 110 | 0.050 |
Why?
|
| Diastole | 1 | 2003 | 67 | 0.050 |
Why?
|
| Protein Kinase C-alpha | 1 | 2003 | 10 | 0.050 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2003 | 19 | 0.050 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2003 | 10 | 0.050 |
Why?
|
| Autoantigens | 1 | 2003 | 53 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 1044 | 0.050 |
Why?
|
| Dactinomycin | 1 | 2003 | 23 | 0.050 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 15 | 0.050 |
Why?
|
| Vasculitis | 1 | 2003 | 30 | 0.050 |
Why?
|
| Collagenases | 1 | 2003 | 24 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 985 | 0.050 |
Why?
|
| Free Radicals | 1 | 2003 | 28 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2004 | 191 | 0.050 |
Why?
|
| Mutation | 2 | 2006 | 1351 | 0.050 |
Why?
|
| Tachycardia, Ventricular | 1 | 2003 | 46 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2005 | 244 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2003 | 45 | 0.050 |
Why?
|
| Carotid Artery, External | 1 | 2002 | 4 | 0.050 |
Why?
|
| Neutrophil Activation | 1 | 2002 | 13 | 0.050 |
Why?
|
| Lovastatin | 1 | 2002 | 9 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2010 | 54 | 0.050 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2002 | 39 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2002 | 11 | 0.050 |
Why?
|
| Nitroglycerin | 1 | 2002 | 8 | 0.050 |
Why?
|
| Motor Activity | 1 | 2003 | 224 | 0.050 |
Why?
|
| Hypercalcemia | 1 | 2002 | 34 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 47 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 312 | 0.050 |
Why?
|
| Diet, Atherogenic | 1 | 2002 | 10 | 0.050 |
Why?
|
| Particle Size | 1 | 2022 | 78 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2022 | 88 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2003 | 240 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2004 | 334 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 89 | 0.050 |
Why?
|
| Aorta, Abdominal | 1 | 2002 | 39 | 0.050 |
Why?
|
| Muscle, Smooth | 1 | 2002 | 64 | 0.050 |
Why?
|
| Cattle | 1 | 2002 | 207 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2003 | 230 | 0.050 |
Why?
|
| Dietary Proteins | 1 | 2004 | 252 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2013 | 119 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2006 | 1532 | 0.050 |
Why?
|
| Glucosides | 1 | 2020 | 24 | 0.040 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2020 | 17 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 22 | 0.040 |
Why?
|
| Lysosomes | 1 | 2021 | 78 | 0.040 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 69 | 0.040 |
Why?
|
| Inpatients | 1 | 2022 | 205 | 0.040 |
Why?
|
| Skin | 1 | 2003 | 418 | 0.040 |
Why?
|
| Random Allocation | 2 | 2015 | 287 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2003 | 689 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 111 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2020 | 34 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2020 | 47 | 0.040 |
Why?
|
| Ischemia | 2 | 2014 | 153 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 331 | 0.040 |
Why?
|
| Peritoneal Dialysis | 1 | 2019 | 33 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 443 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 92 | 0.040 |
Why?
|
| Gene Transfer Techniques | 2 | 2010 | 40 | 0.040 |
Why?
|
| Patient Selection | 1 | 2019 | 259 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2018 | 182 | 0.040 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2017 | 15 | 0.030 |
Why?
|
| Acetylation | 1 | 2017 | 96 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2017 | 44 | 0.030 |
Why?
|
| Bioprosthesis | 1 | 2017 | 40 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2017 | 54 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2017 | 60 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 111 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2015 | 21 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2015 | 69 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 46 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2015 | 67 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 93 | 0.030 |
Why?
|
| NAD | 1 | 2014 | 45 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 38 | 0.030 |
Why?
|
| Extremities | 1 | 2014 | 32 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 406 | 0.030 |
Why?
|
| Flavonoids | 2 | 2004 | 54 | 0.030 |
Why?
|
| Health Planning | 1 | 2014 | 13 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2015 | 352 | 0.030 |
Why?
|
| Lung | 1 | 2018 | 502 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2014 | 42 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 106 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2005 | 179 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 57 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 46 | 0.030 |
Why?
|
| Leukocyte Rolling | 1 | 2012 | 1 | 0.020 |
Why?
|
| Venules | 1 | 2012 | 2 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2014 | 364 | 0.020 |
Why?
|
| Aryldialkylphosphatase | 1 | 2012 | 4 | 0.020 |
Why?
|
| Electron Transport Complex II | 1 | 2012 | 7 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 43 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 135 | 0.020 |
Why?
|
| Epitopes | 1 | 2012 | 65 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 3684 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2020 | 4030 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2012 | 120 | 0.020 |
Why?
|
| Succinimides | 1 | 2011 | 5 | 0.020 |
Why?
|
| Fluoresceins | 1 | 2011 | 9 | 0.020 |
Why?
|
| Mesentery | 1 | 2011 | 14 | 0.020 |
Why?
|
| Splanchnic Circulation | 1 | 2011 | 32 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 236 | 0.020 |
Why?
|
| Amiodarone | 1 | 2011 | 23 | 0.020 |
Why?
|
| Indium Radioisotopes | 1 | 2010 | 2 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 591 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 84 | 0.020 |
Why?
|
| Liposomes | 1 | 2010 | 53 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2017 | 1066 | 0.020 |
Why?
|
| Gadolinium | 1 | 2010 | 44 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2010 | 92 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 121 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2010 | 195 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 868 | 0.020 |
Why?
|
| Adiponectin | 1 | 2009 | 46 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2009 | 11 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 205 | 0.020 |
Why?
|
| Drug Stability | 1 | 2009 | 38 | 0.020 |
Why?
|
| Phospholipids | 1 | 2009 | 59 | 0.020 |
Why?
|
| Child | 1 | 2020 | 7157 | 0.020 |
Why?
|
| Nephritis | 1 | 2007 | 23 | 0.020 |
Why?
|
| Epithelium | 1 | 2007 | 65 | 0.020 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2007 | 61 | 0.020 |
Why?
|
| Rats, Zucker | 1 | 2007 | 73 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2007 | 48 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2009 | 719 | 0.020 |
Why?
|
| Dyspnea | 1 | 2007 | 78 | 0.020 |
Why?
|
| Fatigue | 1 | 2007 | 125 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2005 | 12 | 0.020 |
Why?
|
| Capsid Proteins | 1 | 2005 | 24 | 0.020 |
Why?
|
| Reperfusion | 1 | 2005 | 11 | 0.020 |
Why?
|
| CHO Cells | 1 | 2005 | 125 | 0.020 |
Why?
|
| COS Cells | 1 | 2005 | 85 | 0.010 |
Why?
|
| Cricetinae | 1 | 2005 | 194 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2005 | 98 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2005 | 42 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2005 | 44 | 0.010 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2007 | 167 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2005 | 195 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2005 | 140 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2003 | 10 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2003 | 13 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2003 | 16 | 0.010 |
Why?
|
| HSP72 Heat-Shock Proteins | 1 | 2003 | 9 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2003 | 21 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2004 | 194 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2003 | 29 | 0.010 |
Why?
|
| Oxidoreductases | 1 | 2003 | 59 | 0.010 |
Why?
|
| Catalase | 1 | 2003 | 74 | 0.010 |
Why?
|
| Polyisoprenyl Phosphates | 1 | 2003 | 13 | 0.010 |
Why?
|
| Anticholesteremic Agents | 1 | 2003 | 31 | 0.010 |
Why?
|
| Rest | 1 | 2003 | 60 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2003 | 58 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 400 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2003 | 117 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2003 | 93 | 0.010 |
Why?
|
| Insulin | 1 | 2005 | 481 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2003 | 263 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 147 | 0.010 |
Why?
|
| Kinetics | 1 | 2003 | 623 | 0.010 |
Why?
|